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Background/Aims: Erlotinib and gemcitabine combined 
chemotherapy is becoming the treatment of choice in ad-
vanced pancreatic cancer. We evaluated the effectiveness of 
treatment with erlotinib plus gemcitabine and the prognostic 
factors for chemotherapeutic response in Korean pancreatic 
cancer patients. Methods: Sixty-nine patients with advanced 
pancreatic cancer who were treated with daily erlotinib 100 
mg orally and gemcitabine 1,000 mg/m2/30 min intrave-
nous infusion on days 1, 8, and 15 of each 4-week cycle 
from 2006 to 2009 were included in this study. This study 
was a phase II single-center trial. Results: All 69 patients 
with advanced pancreatic cancer were chemotherapy-naïve. 
The objective response rate was 18.8%, and the overall 
tumor-stabilization rate was 49.2%. The median overall sur-
vival was 7.7 months (95% confidence interval [CI], 6.0 to 
9.4 months). The median progression-free survival was 1.9 
months (95% CI, 1.4 to 2.5 months). Prognostic factors for 
good chemotherapeutic response were good performance 
status and the presence of skin rash during chemotherapy. 
Patients with lower performance scores showed worse che-
motherapeutic responses (odds ratio [OR], 7.6; 95% CI, 2.4 
to 24.8). Poor responses were predicted by the absence of 
skin rash during chemotherapy (OR, 3.0; 95% CI, 1.4 to 6.3). 
Conclusions: Erlotinib and gemcitabine chemotherapy is a 
tolerable treatment regimen and has a favorable therapeutic 
effect in Korean patients with advanced pancreatic cancer. 
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INTRODUCTION
Pancreatic cancer is a devastating disease and one of the ma-
jor causes of cancer-related deaths worldwide. It has also been 
reported as the fifth leading cause of cancer-related mortality in 
Korea. Furthermore, only 20% of patients with pancreatic can-
cer have a resectable state at the time of diagnosis.1 Recently, 
the incidence of pancreatic cancer has increased in Korea. A 
modern life style and cigarette smoking are the main factors 
underlying the increase in incidence of pancreatic cancer in 
Asian patients.2
Since gemcitabine was approved in 1996 by Food and Drug 
Administration, this purine analog has become the standard of 
treatment for advanced pancreatic cancer, and has been shown 
to improve survival.3,4 However, patients who undergo gem-
citabine-based chemotherapy for advanced pancreatic cancer 
still have an overall survival of under 6 months.5,6
Recently, novel molecular agents that target specific biologic 
pathways that are activated in cancer have been developed to 
treat solid tumors. Epidermal growth factor receptor (EGFR)-
mediated cell signaling is one of the main therapeutic targets 
of these novel molecular agents. EGFR is a member of the ErbB 
family of membrane receptors that are involved in cell differen-
tiation, proliferation, apoptosis, invasion, and metastasis.7 Erlo-
tinib (EGFR tyrosine kinase inhibitor [TKI]) is an orally bioavail-
able small molecule that inhibits the enzymatic activity of EGFR 
by binding at the adenosine triphosphate site of the receptor’s 
tyrosine kinase region.7,8
EGFR targeting has shown promising results in patients with 
advanced pancreatic cancer and nonsmall cell lung cancer 
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(NSCLC).9 In particular, subgroup analysis of previous clinical 
trials in NSCLC showed that certain patients with distinct clini-
cal and histologic characteristics, namely East Asian patients, 
women, and those with adenocarcinoma, responded favorably 
to EGFR TKIs, gefitinib, or erlotinib.9-11 In a recent randomized 
phase III trial in patients from Western countries, those with ad-
vanced pancreatic cancer treated with erlotinib plus gemcitabine 
combined chemotherapy showed better survival than those pa-
tients that received gemcitabine monotherapy.12
In this study, we evaluated the effectiveness of treatment with 
erlotinib plus gemcitabine chemotherapy, and also identified 
prognostic factors of chemotherapeutic response in Korean pa-
tients with advanced pancreatic cancer to see if there is a similar 
ethnical advantage to treatment as has been demonstrated for 
NSCLCs.
MATERIALS AND METHODS
1. Eligibility
Sixty-nine patients with advanced pancreatic cancer who 
were treated with daily erlotinib and gemcitabine on day 1, 8, 
and 15 of each 4 weeks between December 2006 and March 
2009 at Severance Hospital, Yonsei University College of Medi-
cine, Seoul, Korea were included in this phase II trial. Following 
inclusion criteria was used for enrollment. Patients with histo-
logically or cytologically confirmed metastatic pancreatic cancer 
or locally advanced pancreatic cancer were enrolled. In addition, 
patients who had received previous chemotherapy were not 
included. Further eligibility criteria included age >20 years, an 
Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 to 3, and adequate organ function. In detail, bone marrow 
function was adequate as indicated by a white blood cell count 
>3,000/mL, a hemoglobin level >9 g/dL, and a platelet count 
>100,000/mL. Adequate hepatic function was satisfied to a total 
bilirubin level <3 mg/dL with adequate biliary decompression, 
and a serum transaminase level <5 times the upper limit of nor-
mal, and renal function was adequate (a creatinine level <1.5 
mg/dL). All patients were informed of the investigational nature 
of the study.
2. Treatment
All patients received oral administration of erlotinib (100 
mg) daily, and gemcitabine 1,000 mg/m2 was infused intrave-
nously over 30 minutes weekly (days 1, 8, and 15) followed by 
a 1-week rest per 4 weeks cycle.
The primary endpoint was overall survival. The secondary 
endpoints were progression-free survival and response rate. 
Toxicities and risk factors for chemotherapeutic response were 
also evaluated.
3. Response assessment and toxicity profiles
Patients’ medical history, physical examination results, and 
ECOG performance status were evaluated before chemotherapy. 
Laboratory tests, including hematologic, biochemical profiling, 
and tumor marker profiling, were performed, as was computed 
tomography or magnetic resonance imaging. Chemotherapy ef-
ficacy was assessed by monitoring the patients’ responses after 
every 8 weeks of chemotherapy. According to the Response 
Evaluation Criteria In Solid Tumors (RECIST) criteria, a complete 
response (CR) was defined as the disappearance of all measur-
able disease for 8 weeks, a partial response (PR) as at least a 
30% decrease in the sum of the products of maximum diameter 
and a perpendicular diameter of all measurable lesions, stable 
disease (SD) as neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for progressive disease (PD), 
and PD as at least a 20% increase in the sum of the products of 
maximum diameter and a perpendicular diameter of all measur-
able lesions since the treatment started or the appearance of one 
or more new lesions.
Time to progression was defined as the interval between the 
initiation of therapy and the occurrence of disease progression. 
Survival duration was defined as time from the initiation of 
therapy to death, or to last contact.
Patients were divided into two groups according to their 
chemotherapeutic response. Patients with CR, PR, and SD were 
defined as good responders, whereas those with progressed dis-
ease were classified as poor responders. Toxicity assessment was 
based on the World Health Organization toxicity criteria.
4. Statistical analysis
Continuous data are expressed as means±SD or medians 
when appropriate. Categorical data are expressed as the number 
of subjects (or proportion) with a specified condition or clini-
cal variable. The significance of differences between continu-
ous variables was evaluated using Student t-test, while the 
chi-square test was used for categorical data. Median overall 
survival was estimated by Kaplan-Meier analysis. The associa-
tion between progression-free survival and risk variables was 
assessed by multivariate Cox regression analysis. All analyses 
were performed using SPSS version 12.0 (SPSS Inc., Chicago, IL, 
USA). A p<0.05 was considered significant.
RESULTS
1. Patient characteristics
All 69 patients who had not received prior chemotherapy 
after diagnosis were confirmed to have advanced pancreatic 
cancer. Advanced pancreatic cancer was defined as inoper-
able locally advanced cancer (six patients, 8.7%) or distantly 
metastatic cancer (63 patients, 91.3%) at the time of diagnosis. 
The median age was 62 years (range, 31 to 82 years), and 50 
patients (72.5%) were male. Levels of CA19-9 were elevated in 
55 patients (79.7%); the median CA19-9 level was 1,990 U/mL 
(range, 45.3 to 20,000 U/mL). The clinical characteristics of the 
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patients are summarized in Table 1.
2. Objective responses and overall survival
The objective response rate (ORR) is described in Table 2. 
There were no CR, but 13 patients showed PR. The overall ORR 
means percentage of patients whose cancer shrinks or disap-
pears after treatment. ORR was 18.8%, and the tumor stabiliza-
tion rate, including ORR and SD, was 49.3%. The median time 
to progression of disease was 1.9 months (95% CI, 1.4 to 2.5 
months) (Fig. 1). The median overall survival was 7.7 months 
(95% CI, 6.0 to 9.4 months), as shown in Fig. 2. Although pa-
tients with skin rash tended to have better survival, the number 
of overall survival days according to the presence of skin rash 
was not significantly different between the two groups in this 
study (9.1 months in patients with skin rash vs 6.3 months in 
patients without skin rash; p=0.32). Patients were divided into 
two groups according to their response to chemotherapy. The 
good responder group showed better progression-free survival 
than the poor responder group (4.2 months vs 1.4 months; 
p=0.001).
3. Toxicity data
All patients were assessed for toxicity. The most common 
symptoms of toxicity were skin rashes, diarrhea, and thrombo-
cytopenia. The most common adverse event was skin toxicity 
(31.8%). One patients developed chemotherapy-related inter-
stitial lung disease (ILD)-like syndrome. Except for anemia and 
ILD, most of the toxicities were grade 1 or grade 2. All of toxic-
ity profiles are summarized in Table 3.
4. Prognostic factors for chemotherapeutic response
Prognostic factors for poor chemotherapeutic response were 
evaluated by multivariate Cox analysis. Comparison of the good 
and poor responder groups revealed that patients with a tumor 
location other than the pancreatic head, those with no skin 
rashes, and those with a poor performance status (ECOG 3) had 
a poorer chemotherapeutic response (Table 4).
Fig. 1. Progression-free survival (PFS) estimated by Kaplan-Meier 
analysis. PFS (black line) in good responders (orange line) and in 
poor responders (green line; p=0.001).
Table 1. Characteristics of Patients
Characteristic Value
Sex, male/female 50 (72.5)/19 (27.5)
Age, yr 62 (31-83)
Primary tumor site
Head/Body/Tail/Diffuse 27 (39)/17 (24.7)/17 (24.7)/8 (11.6)
Tumor stage
Locally advanced (AJCC III) 6 (8.7)
Distant metastasis (AJCC IV) 63 (91.3)
Performance status
ECOG, 0-1/2/3 41 (59.4)/19 (27.5)/9 (13)
Tumor marker
CA19-9 elevation 55 (79.7)
Personal history
Smoker 17 (24.6)
Diabetes mellitus 24 (34.8)
Data are presented as number (%) or median (range).
AJCC, American Joint Committee on Cancer; ECOG, Eastern Coopera-
tive Oncology Group.
Table 2. Tumor Responses of Patients
Response No. of patients (%)
Partial response 13 (18.8)
Stable disease 21 (30.4)
Progressive disease 24 (34.8)
Not assessable 11 (15.9)
Objective response rate 13 (18.8)
Disease stabilization rate 34 (49.3)
Fig. 2. Overall survival (OS) estimated by Kaplan-Meier analysis. OS 
(black line) in patients with skin rash (orange line) and in patients 
without skin rash (green line; p=0.32).
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DISCUSSION
Despite the inclusion of patients with poor performance status 
(ECOG 3), the median overall survival of patients included in 
this trial was 7.7 months, which represents some improvement 
in survival, consistent with previous phase III gemcitabine and 
erlotinib trials in Western patients with advanced pancreatic 
cancer.12
The main symptoms of EGFR TKI toxicity were diarrhea and 
skin rash.13,14 In general, skin toxicities occur in over 50% pa-
tients treated with EGFR TKI.15 Higher skin toxicity symptoms 
in pancreatic cancer patients treated with EGFR inhibitors have 
been reported to be associated with better overall survival and 
progression-free survival.12 The mechanism of the relationship 
between the presence of skin rash and a good prognosis is not 
clear, but it has been proposed that skin toxicity may be a sur-
rogate indicator of an immune-based local inflammatory reac-
tion at the tumor level that provides antitumor activity.9,15 In 
this trial, one of the risk factors for poor prognosis were patients 
in the group without skin rash like results of other previous 
studies,12 despite the similar overall survival between the two 
groups according to the presence of skin rash (9.1 months vs 
6.3 months; p=0.32). Subgroup analysis was performed in the 
patients with severe skin rash over grade 2 compared to the ab-
sence of skin rash. The median overall survival days shows 9.5 
months versus 6.3 months (p=0.064). Survival gain by statistics 
fails to achieve due to small number of patients in the analysis. 
However, there is significantly better PES in the patients with 
the presence of skin rash over grade 2 compared to no skin rash 
(4.8 months vs 1.4 months; p=0.003). In summary, although 
significant survival benefit was not showed, we could predict 
the good prognosis in the group of patients with skin rash.
Besides the common toxicities like skin rash or diarrhea, 
life-threatening pulmonary toxic effects, like ILD, have been 
reported, albeit rarely. The prevalence of ILD-like syndrome in 
NSCLC patients treated with EGFR TKI ranges from 1% to 3%.16 
Risk factors for this adverse effect have been evaluated in lung 
cancer patients. And these factors are previous chemotherapy 
or radiation therapy of the lung, concomitant pulmonary infec-
tion, preexisting parenchymal lung disease, and metastatic lung 
disease.9 In our study, only one patient (1.5%) showed ILD-like 
syndrome during the fifth cycle of erlotinib and gemcitabine 
treatment. This patient had no previous pulmonary infection or 
any specific lung disease. His case was reported as probably-
related serious adverse event.
The cost-effectiveness of treatment with EGFR TKI has been 
questioned due to the relatively low response rate and high cost 
of this treatment.17 Therefore, it is necessary to be able to identi-
fy subgroups of patients who are likely to derive clinical benefit 
from these agents. Clinical trials in East Asian patients, such as 
this study, are therefore required for anticipating the results of 
NSCLC research.
In this study, subgroup analysis about treatment prognosis 
was performed using several clinical characteristics (Table 4). 
Group of patients with skin rash compared to no rash group, 
and group of patients showing better performance scale (ECOG 
0, 1, or 2) rather than ECOG 3 group are likely to derive clinical 
benefit from these combination chemotherapy. Furthermore, we 
might predict much poorer prognosis in patients with pancreatic 
head cancer than pancreatic body or tail cancer. According to 
our analysis, the most predictable factor about chemotherapeu-
tic response is patient’s performance status, and the next best 
thing is skin rash.
A limitation of this study is that it was not a large-scale phase 
III trial. We did not evaluate molecular predictors, such as EGFR 
expression levels, EGFR mutation status, or K-ras mutation sta-
tus, which are strongly related to pancreatic cancer. However, a 
recent study that evaluated EGFR gene copy number and K-ras 
mutation status as molecular predictive markers in patients with 
advanced pancreatic cancer enrolled in a previous phase III 
Table 3. Toxicity Profiles during Chemotherapy according to World 
Health Organization Criteria
Toxicity
No. of patients
Grade 1 Grade 2 Grade 3 Grade 4
Hematology
Neutropenia 4 2 0 1
Anemia 1 9 8 1
Thrombocytopenia 1 2 3 0
Nonhematology
Nausea/Vomiting 6 1 1 0
Anorexia 4 2 0 0
Urticaria 1 0 0 0
Diarrhea 8 3 2 0
Skin rash 9 9 4 0
ILD 0 0 0 1
ILD, interstitial lung disease.
Table 4. Prognostic Factors of a Poor Chemotherapeutic Response
Factor OR 95% CI p-value
Male sex 1.355 0.618-2.971 0.448
Age (over 50 yr) 1.226 0.559-2.690 0.611
Cancer stage (AJCC IV) 0.414 0.120-1.432 0.164
Cancer location (head) 0.291 0.094-0.898 0.032
No skin rash 3.018 1.448-6.288 0.003
Poor performance (ECOG 3) 7.647 2.360-24.781 0.001
CA19-9 elevation 1.178 0.503-2.760 0.707
OR, odds ratio; CI, confidence interval; AJCC, American Joint Com-
mittee on Cancer; ECOG, Eastern Cooperative Oncology Group.
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gemcitabine plus erlotinib trial reported that these markers were 
not predictive.18 This highlights the need to identify additional 
molecular predictive markers in the future.
In conclusion, erlotinib plus gemcitabine chemotherapy is a 
tolerable treatment regimen and has a favorable therapeutic ef-
fect in Korean patients with unresectable advanced pancreatic 
cancer, similar to EGFR-targeted therapy in Asian patients with 
NSCLC.
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